Leukocare AG, a German biotechnology company specialized in formulation development for biologics, viral vectors and vaccines, has opened its development laboratories and offices in Milford, MA. The recently incorporated Leukocare Inc., a wholly owned subsidiary of Leukocare AG, lays the foundation for supporting U.S.-based clients on site. Leukocare´s headquarters will remain in Martinsried/Munich, Germany.
 
According to the company, being present in the U.S. market offers the opportunity to collaborate closely with customers and partners on tailor-made solutions in the field of drug product formulation development for biopharmaceuticals and advanced therapy medicinal products (ATMP). An in-house biostatistics team adds to more than fifteen years of experience in this area by using best-in-class algorithms and deep learning to provide individually designed solutions in less time.
 
Leukocare´s U.S. offices and laboratories are located at Rentschler Biopharma´s Milford premises, a leading contract development and manufacturing organization (CDMO). Leukocare and Rentschler Biopharma have been sharing a successful global strategic alliance since 2017 to offer integrated best-in-class formulation development services considered at every step of the biopharmaceutical value chain.
 
“I am delighted to announce the opening of Leukocare´s U.S. site today,” said Michael Scholl, chief executive officer, Leukocare. “The company´s outstanding development over the last few years led to our desire of establishing a presence in the largest pharmaceuticals market worldwide. This strategic step enables us to be even closer to both our U.S. and global customers and to better understand and serve their needs.
 
“Furthermore, the existing infrastructure of Rentschler in Milford—that we will partially make use of—allows us to start operations without any delay and thus makes Milford the perfect choice for our newly established U.S. site. We therefore will continue to pursue our strategy of pushing boundaries of biopharmaceutical product development by combining innovative biostatistics, artificial intelligence and vast formulation expertise with first-class analytics.”